AptarGroup, Inc. Reports Strong Second Quarter 2025 Results with Broad-Based Growth and Margin Expansion Across Segments
AptarGroup, a global leader in drug delivery and consumer product dispensing and protection technologies, today announced its financial results for the second quarter ended June 30, 2025. The company reported solid year-over-year growth in sales, profitability, and shareholder returns, with performance driven by all three core segments: Pharma, Beauty, and Closures.
Key Highlights – Second Quarter 2025 vs. Second Quarter 2024
- Reported sales increased 6% to $966 million
- Core sales (excluding currency and acquisitions) rose 3%
- Reported net income grew 24% to $112 million
- Adjusted EBITDA increased 13% to $218 million
- Reported earnings per share (EPS) rose 25% to $1.67
- Adjusted EPS (excluding certain items) increased 18% to $1.66
- Adjusted EBITDA margin expanded by 140 basis points to 22.6%
- $100 million returned to shareholders through dividends and share repurchases
Key Highlights – First Half of 2025 vs. First Half of 2024
- Reported and core sales both grew 2%
- Net income rose 10% to $191 million
- Adjusted EBITDA climbed 8% to $402 million
- Reported EPS increased 10% to $2.83
- Adjusted EPS rose 8% to $2.86
- Total shareholder returns reached $210 million in the first six months
Commenting on the quarter’s performance, Aptar President and CEO Stephan B. Tanda said,
Segment Performance Overview
Pharma Segment
The Pharma segment continued to demonstrate its strategic importance and financial strength. For Q2 2025, reported sales in this segment grew 7%, with core sales rising 3%. Growth was fueled by increased demand in key business lines, including Prescription, Injectables, and Active Material Science.
- Prescription division saw sustained demand for proprietary drug delivery systems used in emergency treatments (e.g., rescue inhalers and epinephrine), as well as for therapies related to asthma, COPD, and ophthalmic applications.
- Injectables achieved 9% core sales growth, supported by higher orders for premium elastomeric components. These components are essential in administering biologics and GLP-1-based drugs, which continue to grow in use globally.
- Active Material Science saw core sales climb 11%, driven by greater adoption of active film solutions for drug packaging. These technologies help extend product shelf life and stability—an increasing priority for pharmaceutical manufacturers.
Adjusted EBITDA margin for the Pharma segment expanded by 130 basis points year-over-year, reaching an impressive 35.4%, bolstered by strong royalty revenues and favorable product mix.
Beauty Segment
Aptar Beauty reported a 4% increase in sales and a 1% rise in core sales compared to the same quarter last year. This growth was primarily attributed to increased tooling sales in the personal care and beauty end markets.
Within this segment:
- Personal care products experienced continued strong growth, particularly in Europe and North America.
- Beauty dispensing systems, particularly in fragrance and full pack solutions, faced headwinds due to delayed new product launches and continued uncertainties around global tariffs, which impacted customer purchasing behavior.
- China’s beauty market showed positive signs of recovery. Sales of dispensing systems rose in the region, largely due to increased demand from regional customers rather than global brands.
Despite the mixed results across categories, Aptar Beauty still achieved a 20 basis point improvement in adjusted EBITDA margin, which increased to 14.1%, reflecting operational efficiencies and a gradual rebound in demand.
Closures Segment
Aptar’s Closures segment delivered the strongest revenue performance of all three divisions this quarter, with reported sales up 8% and core sales up 7%. The growth was primarily driven by strong demand in the food and beverage markets.
Key growth drivers included:
- Increased sales of closures for sauces, dressings, and functional beverages.
- Broad-based growth across almost every global region, reflecting successful customer engagements and market penetration.
- Product innovations tailored for sustainability and ease of use, which continue to resonate with both brands and end consumers.
Adjusted EBITDA margin in the Closures segment expanded by 130 basis points, reaching 16.9%, demonstrating solid cost control and favorable pricing dynamics.
Earnings and Profitability
For Q2 2025, Aptar reported earnings per share of $1.67, up 25% from the prior-year quarter. Adjusted EPS—excluding restructuring expenses, acquisition-related costs, and unrealized gains or losses on equity investments—was $1.66, representing an 18% increase compared to $1.41 in Q2 2024.
The company’s effective tax rate for the quarter declined to 20.0%, compared to 23.5% in the prior-year period. This reduction was largely driven by anticipated tax benefits from ongoing tax planning strategies and increased tax advantages related to share-based compensation.
First Half of 2025: Continued Strength
Over the first six months of 2025, Aptar reported total sales of $1.85 billion, a 2% increase from the $1.83 billion recorded in the same period last year. Core sales also rose 2%.
The company’s net income for the first half reached $191 million, a 10% increase from the prior year, while adjusted EBITDA totaled $402 million, reflecting an 8% increase. EPS for the first six months stood at $2.83, up from $2.57 in the previous year, while adjusted EPS came in at $2.86, an 8% improvement year-over-year.
The effective tax rate for the six-month period was 22.5%, slightly higher than the prior year’s 22.1%, but still within management’s guidance range.
Shareholder Returns and Capital Allocation
Aptar continued to demonstrate its commitment to shareholder value through capital returns. During the second quarter alone, the company returned $100 million to shareholders through a combination of dividends and share repurchases. This brought total returns to $210 million for the first half of 2025.
This disciplined approach to capital allocation underscores Aptar’s confidence in its cash generation capabilities and its focus on long-term value creation.
